• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alexion Shareholders Approve Acquisition by AstraZeneca

    5/11/21 9:28:00 AM ET
    $ALXN
    Major Pharmaceuticals
    Health Care
    Get the next $ALXN alert in real time by email

    Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today.

    Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: "We're very pleased with today's affirmative shareholder vote, which brings us one step closer to completing a transaction that will accelerate the combined company's ability to develop and provide access to life-changing medicines for patients with rare and devastating diseases around the world."

    Subject to receipt of additional regulatory clearances, the acquisition is expected to close in the third quarter of 2021.

    About Alexion

    Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: www.alexion.com.

    [ALXN-G]

    Forward-Looking Statement

    This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Alexion's and AstraZeneca's control. Statements in this communication regarding Alexion, AstraZeneca and the combined company that are forward-looking, including anticipated benefits of the proposed transaction, the impact of the proposed transaction on Alexion's and AstraZeneca's businesses and future financial and operating results, the amount and timing of synergies from the proposed transaction, the terms and scope of the expected financing for the proposed transaction, the aggregate amount of indebtedness of the combined company following the closing of the proposed transaction, are based on management's estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond Alexion's and AstraZeneca's control. These factors include, among other things, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. Additional information concerning these risks, uncertainties and assumptions can be found in Alexion's and AstraZeneca's respective filings with the SEC, including the risk factors discussed in Alexion's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, in AstraZeneca's most recent Annual Report on Form 20-F and in each company's future filings with the SEC. Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, the risks that: a condition to the closing the proposed acquisition may not be satisfied; a regulatory approval that may be required for the proposed acquisition is delayed, is not obtained or is obtained subject to conditions that are not anticipated; AstraZeneca is unable to achieve the synergies and value creation contemplated by the proposed acquisition; AstraZeneca is unable to promptly and effectively integrate Alexion's businesses; management's time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company declines following the proposed acquisition; legal proceedings are instituted against Alexion, AstraZeneca or the combined company; Alexion, AstraZeneca or the combined company is unable to retain key personnel; and the announcement or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of Alexion or AstraZeneca or on Alexion's or AstraZeneca's operating results. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Alexion or AstraZeneca. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the proposed transaction and/or Alexion or AstraZeneca, AstraZeneca's ability to successfully complete the proposed transaction and/or realize the expected benefits from the proposed transaction. You are cautioned not to rely on Alexion's and AstraZeneca's forward-looking statements. These forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither Alexion nor AstraZeneca assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005775/en/

    Get the next $ALXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALXN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALXN
    Leadership Updates

    Live Leadership Updates

    See more
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

      12/1/20 4:30:00 PM ET
      $LLY
      $DRNA
      $NVO
      $ALXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $ALXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: COUGHLIN CHRISTOPHER J returned 42,347 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:54:11 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: FRIEDMAN PAUL A returned 12,840 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:51:08 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: SARIN ARADHANA returned 120,253 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:52:30 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/16/21 12:23:41 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/12/21 6:51:47 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/10/21 10:30:29 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moderna Set to Join S&P 500

      NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 21, 2021 S&P 500 Addition Moderna MRNA Health Care S&P 500 Deletion Alexion Pharmaceuticals ALXN Health Care For more information about S&P Dow Jones Indices, please

      7/15/21 7:01:00 PM ET
      $SPGI
      $ALXN
      $AZN
      $MRNA
      Finance: Consumer Services
      Finance
      Major Pharmaceuticals
      Health Care
    • Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

      – Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as early as Week 1, sustained for 52 weeks – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS® (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met, with high statistical significance, its primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, a patient-reported assessment, at Week 26, and for the s

      7/15/21 4:05:00 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

      NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Honeywell International Inc. (NASDAQ:HON), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) and the NASDAQ-100 Ex-Technology Index (NASDAQ:NDXX) prior to market open on Wednesday, July 21, 2021. Honeywell International Inc. will replace Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the NASDAQ-100 Index®, the NASDAQ-100 Equal Weighted Index and the NASDAQ-100 Ex-Technology Index. For more information about the company, go to https://www.honeywell.com/ . About Nasdaq Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital ma

      7/14/21 8:00:00 PM ET
      $ALXN
      $NDAQ
      $HON
      Major Pharmaceuticals
      Health Care
      Investment Bankers/Brokers/Service
      Finance

    $ALXN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alexion Pharmaceuticals, Inc.

      15-12G - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      8/2/21 9:02:07 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.

      EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      7/26/21 12:15:08 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.

      EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      7/26/21 12:15:53 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alexion Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Alexion Pharma from Perform to Outperform and set a new price target of $205.00

      5/5/21 6:41:15 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Credit Suisse resumed coverage on Alexion Pharma with a new price target

      Credit Suisse resumed coverage of Alexion Pharma with a rating of Neutral and set a new price target of $190.00

      4/26/21 8:53:18 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Alexion Pharma downgraded by SVB Leerink

      SVB Leerink downgraded Alexion Pharma from Outperform to Mkt Perform

      3/23/21 7:28:52 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care